ADMA (ADMA Biologics) Tariff Resilience Score: 6/10 (As of Jun. 29, 2026)


ADMA ADMA Biologics Inc ADMA
64 GF Score
Price $8.73
GF Value $17.95
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is ADMA Biologics Tariff Resilience Score?

ADMA Biologics ADMA +0.34% 64 Tariff Resilience Score is 6 as of Jun. 29, 2026. GuruFocus rates ADMA with a GF Score™ of 64/100 and a GF Value™ of $17.95 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 1,376 Biotechnology companies, ADMA Biologics ranks better than 75.94% on this metric.

ADMA Biologics has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

ADMA Biologics has ADMA's focus on biologics, primarily for the U.S. market, limits its exposure to international tariffs. However, reliance on imported raw materials could pose some risk if tariffs affect supply costs.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes ADMA Biologics might have Average Resilient.

ADMA Biologics  (NAS:ADMA) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

ADMA Biologics Tariff Resilience Score Related Terms

ADMA vs ZLAB, HRMY, STOK: Tariff Resilience Score Comparison

For the Biotechnology subindustry, ADMA Biologics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ADMA Biologics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ADMA Biologics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where ADMA Biologics's Tariff Resilience Score falls into.


ADMA
64GF Score
ADMA Biologics Inc ADMA
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
ADMA Biologics (ADMA) has a Tariff Resilience Score of 6 as of Jun. 29, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, ADMA Biologics ranks #331 out of 1376 companies in the Biotechnology industry, placing it in the top 24.1%.
Is ADMA Biologics' Tariff Resilience Score too high?
ADMA Biologics' current Tariff Resilience Score is 6. The Biotechnology industry median Tariff Resilience Score is 4.00. ADMA Biologics' value of 6 is 50% above this industry median. Based on the distribution chart, ADMA Biologics ranks #331 out of 1376 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, ADMA Biologics has a GF Score™ of 64/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ADMA Biologics' Tariff Resilience Score compare to ZLAB and HRMY?
According to the Biotechnology industry distribution chart, ADMA Biologics ranks #331 out of 1376 companies for Tariff Resilience Score. This places ADMA Biologics in the top 24% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. ADMA Biologics' value of 6 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,376 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ADMA Biologics's current Tariff Resilience Score of 6 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ADMA Biologics's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADMA Biologics stock overvalued right now?
Based on GuruFocus' analysis, ADMA Biologics (ADMA) is currently considered Significantly Undervalued. The stock's GF Value™ is $17.95, compared to a current price of $8.73 — trading 51.4% below its estimated fair value. The current Tariff Resilience Score is 6 and 50% above the Biotechnology industry median of 4.00. ADMA Biologics' overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For ADMA Biologics (ADMA), the current Tariff Resilience Score is 6 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ADMA Biologics (ADMA) Overvalued in 2026?

Based on GuruFocus' analysis, ADMA Biologics stock appears to be undervalued. The current stock price of $8.73 is trading 51.4% below its estimated GF Value™ of $17.95. GuruFocus considers ADMA Biologics to be Significantly Undervalued.

Key valuation signals for ADMA:

  • Tariff Resilience Score: 6
  • GF Value™: $17.95 vs. price of $8.73 (51.4% below fair value)
  • GF Score™: 64/100 with 2 warning signs
  • Industry Position: 50% above the Biotechnology median (#331 of 1376)

No single metric tells the full story. See the ADMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ADMA Biologics Business Description

Address 465 State Route 17, Ramsey, NJ, USA, 07446
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
64GF Score

Get the complete analysis for ADMA

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.73
Price
$17.95
GF Value